Survey: Preferred practice patterns in the diagnosis of mucous membrane pemphigoid amongst cornea specialists.

Autor:	Moussa S; Faculty of Medicine, McGill University, Montréal, Canada., Tong M; Ophthalmology department, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada., Robert MC; Ophthalmology department, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada., Harissi-Dagher M; Ophthalmology department, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada., Ahmad S; Department of Ophthalmology, Moorfields Eye Hospital, London, UK., Jabbour S; Ophthalmology department, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.
Jazyk:	angličtina
Zdroj:	European journal of ophthalmology [Eur J Ophthalmol] 2024 Jan; Vol. 34 (1), pp. 112-118. Date of Electronic Publication: 2023 May 24.
DOI:	10.1177/11206721231178110
Abstrakt:	Purpose: To evaluate preferred diagnostic tools and treatment decision-making factors in cases suspicious of mucous membrane pemphigoid (MMP) amongst ophthalmologists and cornea specialists. Methods: Web-based survey, consisting of 14 multiple choice questions, posted to the Cornea Society Listserv Keranet, the Canadian Ophthalmological Society Cornea Listserv, and the Bowman Club Listserv. Results: One hundred and thirty-eight ophthalmologists participated in the survey. Eighty-six percent (86%) of respondents were cornea trained and practiced in either North America or Europe (83%). Most respondents (72%) routinely perform conjunctival biopsies for all suspicious cases of MMP. For those who do not, fear that biopsy will exacerbate inflammation was the most common reason to defer investigation (47%). Seventy-one percent (71%) performed biopsies from perilesional sites. Ninety-seven percent (97%) ask for direct (DIF) studies and 60% for histopathology in formalin. Most do not recommend biopsy at other non-ocular sites (75%), nor do they perform indirect immunofluorescence for serum autoantibodies (68%). Immune-modulatory therapy is started following positive biopsy results for most (66%), albeit most (62%) would not let a negative DIF influence the choice of starting treatment should there be clinical suspicion of MMP. Differences in practice patterns as they relate to level of experience and geographical location are contrasted to the most up-to-date available guidelines. Conclusion: Responses to the survey suggest that there is heterogeneity in certain practice patterns for MMP. Biopsy remains an area of controversy in dictating treatment plans. Identified areas of need should be targeted in future research. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu